Payload Information
General Information of This Payload
| Payload ID | PAY0VOPTD |
|||||
|---|---|---|---|---|---|---|
| Name | BGA7650 Payload |
|||||
| Synonyms |
BGA7650 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C32H44ClN3O9 |
|||||
| Isosmiles | CN[C@H](C(O[C@H]([C@]1([C@]([H])([C@@H]([C@@]2(C[C@@](O)(NC(O2)=O)[C@@H](/C=C/C=C(C)/CC3=CC4=C(C(OC)=C3)Cl)OC)[H])C)O1)C)CC(N4C)=O)=O)C |
|||||
| InChI |
InChI=1S/C32H44ClN3O9/c1-17-10-9-11-24(42-8)32(40)16-23(43-30(39)35-32)18(2)28-31(4,45-28)25(44-29(38)19(3)34-5)15-26(37)36(6)21-13-20(12-17)14-22(41-7)27(21)33/h9-11,13-14,18-19,23-25,28,34,40H,12,15-16H2,1-8H3,(H,35,39)/t18-,19+,23+,24-,25+,28+,31+,32+/m1/s1
|
|||||
| InChIKey |
ANHBJISROJTYCJ-VLUFCZTBSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
650.169 |
Polar area |
148.19 |
||
Complexity |
1413.328042 |
xlogp Value |
3.2755 |
|||
Heavy Count |
45 |
Rot Bonds |
5 |
|||
Hbond acc |
10 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
BGA7650 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
22%
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
Human patient-derived gastric tumors were induced on the right flank by a subcutaneous injection. When tumor volume reached approximately 200 mm3 in size, mice were randomized into 5 groups with 8, 9, and 9 animals in vehicle, BGA7650, and BGA9962 groups on Day 0, respectively. After ensuring all cohorts hadapproximately equal average tumor volumes to start, animals were intravenously
administered vehicle, BGA7650 (4 mg/kg) on treatment Day 1. Animal body weight and tumor volume were measured twice weekly.
Click to Show/Hide
|
||||
| In Vivo Model | Human patient-derived gastric xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.16 nM
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
NCI-H2122 cells were plated at a density of 2000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H2122 cells | CVCL_1531 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.55 nM
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
MKN45 cells were plated at a density of 5000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.44 nM
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
Ls147T cells were plated at a density of 5000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Colon adenocarcinoma | Ls147T cells | CVCL_1384 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
20 nM
|
Negative CEA expression (CEA-) | ||
| Method Description |
MDA-MB-231 cells were plated at a density of 2000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||